Preclinical News and Research

RSS

New study unlocks hope for immunotherapy in metastatic prostate cancer

Immunotherapy has been disappointing as a prostate cancer treatment, but a new Columbia study suggests that the powerful treatments have potential when the disease starts to spread.

12 Dec 2023

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third-generation anti-CD19 chimeric antigen receptor (CAR) T-cell therapy to be presented at the American Society of Hematology (ASH) Annual Meeting in San Diego on 11 December, 3pm.

11 Dec 2023

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.

11 Dec 2023

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine's Abramson Cancer Center.

11 Dec 2023

Vanderbilt's potential schizophrenia treatment enters phase 1 clinical trials

A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S. Food and Drug Administration for use in phase 1 clinical trials-;the third WCNDD therapeutic to reach that benchmark.

7 Dec 2023

Thalamus-targeted deep brain stimulation improves cognition in brain injury patients

Study shows that deep brain stimulation (DBS) of the central lateral thalamic nuclei and medial dorsal tegmental tract improves executive function in patients with moderate-severe traumatic brain injury, offering a potential new treatment approach.

6 Dec 2023

Transplantation of older organs may accelerate aging in younger people

Most organ transplantations involve supply from older donors to younger recipients. Aging cells can become senescent, a condition in which they stop multiplying and secrete chemicals that negatively affect neighboring cells.

5 Dec 2023

Targeting Alzheimer's with cell-specific genetics

Developing treatments for Alzheimer's disease (AD) is difficult because complex underlying mechanisms drive different types of cells that may contribute to the disorder.

5 Dec 2023

How dietary restrictions, including intermittent fasting, impact gut microbiota and overall human health

Preclinical and clinical data to analyze gut microbial alterations in various dietary conditions.

5 Dec 2023

Novel mRNA vaccine GLB-COV2-043 shows high efficacy against COVID-19 variants in early trials

The safety, efficacy, and immunogenicity of a mRNA-based vaccine.

5 Dec 2023

Controlling high blood pressure may not be enough to prevent related cognitive declines, study finds

Researchers at Weill Cornell Medicine have found that controlling high blood pressure may not be enough to prevent associated cognitive declines.

4 Dec 2023

Experimental deep brain stimulation offers hope to treat cognitive deficits after traumatic brain injuries

Five people who had life-altering, seemingly irreversible cognitive deficits following moderate to severe traumatic brain injuries showed substantial improvements in their cognition and quality of life after receiving an experimental form of deep brain stimulation (DBS) in a phase 1 clinical trial.

4 Dec 2023

Neuroimaging and network modeling tools shed light on Alzheimer's disease in animal models

Indiana University researchers are collaborating on a novel approach to use neuroimaging and network modeling tools-;previously developed to analyze brains of patients in the clinic-;to investigate Alzheimer's disease progression in preclinical animal models.

4 Dec 2023

CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing

CN Bio today announced its PhysioMimix® assay for Non-alcoholic steatohepatitis (NASH).

From CN-Bio 4 Dec 2023

Texas Children's Hospital delivers first-ever gene therapy for Rett syndrome

Texas Children's Hospital, an internationally-recognized, top-ranked children's hospital and pediatric research center affiliated with Baylor College of Medicine, is the first to deliver a novel gene therapy to treat Rett syndrome in pediatric patients.

1 Dec 2023

Scientists uncover new therapeutic targets for high-risk pediatric leukemia

Scientists at St. Jude Children's Research Hospital comprehensively identified genes directly regulated by a protein associated with high-risk pediatric leukemias.

28 Nov 2023

FDA awards grant for phase 1 clinical trial of experimental AML/MDS treatment

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)-;two related blood diseases that disproportionally strike older adults-;are notoriously difficult to treat and associated with high relapse rates.

28 Nov 2023

JMU Würzburg professor wins ERC Consolidator Grant to advance research on ferroptosis

With the coveted Consolidator Grants totalling two million euros, the European Research Council (ERC) supports outstanding scientists whose work promises further top achievements. José Pedro Friedmann Angeli, Professor of Translational Cell Biology at Rudolf Virchow Centre - Centre for Integrative and Translational Bioimaging at Julius-Maximilians-Universität (JMU) Würzburg, now belongs to this group.

23 Nov 2023

CN Bio wins ‘Most Impactful Industry Collaboration of the Year’ at the OBN Awards 2023 for ongoing research with the FDA

CN Bio has received the ‘Most Impactful Industry Collaboration of the Year’ at the 2023 OBN Awards.

From CN-Bio 23 Nov 2023

AmoyDx and CST Expand Existing Partnership for the Development of Companion Diagnostics (CDx) to Support Precision Oncology

Cell Signaling Technology (CST), a life science biotechnology company and leading provider of antibodies, kits, and services, and Amoy Diagnostics Co., Ltd. (AmoyDx), a China-based innovative molecular diagnostics company in the field of precision oncology, announced today the expansion of their ongoing partnership for companion diagnostic (CDx) development in China.

From Cell Signaling Technology 23 Nov 2023

Preclinical News and Research

New study unlocks hope for immunotherapy in metastatic prostate cancer

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Vanderbilt's potential schizophrenia treatment enters phase 1 clinical trials

Thalamus-targeted deep brain stimulation improves cognition in brain injury patients

Transplantation of older organs may accelerate aging in younger people

Targeting Alzheimer's with cell-specific genetics

How dietary restrictions, including intermittent fasting, impact gut microbiota and overall human health

Novel mRNA vaccine GLB-COV2-043 shows high efficacy against COVID-19 variants in early trials

Controlling high blood pressure may not be enough to prevent related cognitive declines, study finds

Experimental deep brain stimulation offers hope to treat cognitive deficits after traumatic brain injuries

Neuroimaging and network modeling tools shed light on Alzheimer's disease in animal models

CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing

Texas Children's Hospital delivers first-ever gene therapy for Rett syndrome

Scientists uncover new therapeutic targets for high-risk pediatric leukemia

FDA awards grant for phase 1 clinical trial of experimental AML/MDS treatment

JMU Würzburg professor wins ERC Consolidator Grant to advance research on ferroptosis

CN Bio wins ‘Most Impactful Industry Collaboration of the Year’ at the OBN Awards 2023 for ongoing research with the FDA

AmoyDx and CST Expand Existing Partnership for the Development of Companion Diagnostics (CDx) to Support Precision Oncology

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News